肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：胞质Cyclin E预测乳腺癌患者肿瘤复发

2017-07-02 MedSci MedSci原创

乳腺癌CyclinE复发
关注

利用Western blot检测小分子量cyclin E（LMW-E）可以作为乳腺癌患者生存时间减少的预测因素。但是其临床应用较难。CLIN CANCER RES近期发表了一篇文章，研究cyclin E胞质染色作为不同类型乳腺癌不良预后的预测因素。

利用Western blot检测小分子量cyclin E（LMW-E）可以作为乳腺癌患者生存时间减少的预测因素。但是其临床应用较难。CLIN CANCER RES近期发表了一篇文章，研究cyclin E胞质染色作为不同类型乳腺癌不良预后的预测因素。

作者分析了4个不同研究共2494例乳腺癌患者乳腺癌标本的cyclin E亚细胞定位。这些患者中303例来自前瞻性研究，2191例来自回顾性研究（NCI、MDA、UK）。4个研究的平均随访时间分别为8.0年，10.1年，13.5年和5.7年。研究发现免疫组化检测到的cyclin E亚细胞分布与Western blot检测到的全长亚型（核内）以及低分子量形态亚型（胞质内）有关。多变量分析表明，在3个研究（NCI、MDA、UK）的所有乳腺癌亚型中，与其他预后因素相比胞质cyclin E染色与更高的复发风险有关。在MDA研究中，胞质cyclin E染色作为预后因素的作用优于Ki67及其他变量。

文章最后认为，在不同研究及不同亚型乳腺癌中均发现胞质cyclin E染色可以辨别具有高危复发可能的患者。这些患者接受靶向cyclin E致癌亚型的治疗可能会有更大的受益。

原始出处：
Kelly K.Hunt,Cansu Karakas,et al.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.CLIN CANCER RES.June 2017 doi:10.1158/1078-0432.CCR-16-2217

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705588, encodeId=232d1e0558802, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat Jul 08 09:49:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224215, encodeId=9dc622421589, content=文章不错，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jul 20 10:38:31 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571043, encodeId=45a915e104391, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 04 09:49:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217975, encodeId=12f021e975af, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 03 06:44:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217864, encodeId=b58f21e864e1, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 02 21:02:33 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-08 AspirantSuo

    #肿瘤复发#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1705588, encodeId=232d1e0558802, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat Jul 08 09:49:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224215, encodeId=9dc622421589, content=文章不错，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jul 20 10:38:31 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571043, encodeId=45a915e104391, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 04 09:49:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217975, encodeId=12f021e975af, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 03 06:44:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217864, encodeId=b58f21e864e1, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 02 21:02:33 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-20 1e10c84am36(暂无匿称)

    文章不错，谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1705588, encodeId=232d1e0558802, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat Jul 08 09:49:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224215, encodeId=9dc622421589, content=文章不错，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jul 20 10:38:31 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571043, encodeId=45a915e104391, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 04 09:49:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217975, encodeId=12f021e975af, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 03 06:44:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217864, encodeId=b58f21e864e1, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 02 21:02:33 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-04 智慧医人

    #乳腺癌患者#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1705588, encodeId=232d1e0558802, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat Jul 08 09:49:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224215, encodeId=9dc622421589, content=文章不错，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jul 20 10:38:31 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571043, encodeId=45a915e104391, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 04 09:49:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217975, encodeId=12f021e975af, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 03 06:44:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217864, encodeId=b58f21e864e1, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 02 21:02:33 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 189****7206

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1705588, encodeId=232d1e0558802, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Sat Jul 08 09:49:00 CST 2017, time=2017-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224215, encodeId=9dc622421589, content=文章不错，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jul 20 10:38:31 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571043, encodeId=45a915e104391, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jul 04 09:49:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217975, encodeId=12f021e975af, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Mon Jul 03 06:44:57 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217864, encodeId=b58f21e864e1, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Jul 02 21:02:33 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 清风拂面

    学习了，谢谢分享

    0

相关资讯

Nature：基因组“暗物质”帮助科学家找到治疗乳腺癌新方法！

虽然蛋白质编码的基因突变在癌症基因组中占据了首要位置，但事实上，非编码基因在推动肿瘤生长的过程中也起着不容忽视的作用。近期，一项新的研究揭示了乳腺癌复发性突变等九个非编码元素。

CLIN CANCER RES：DC疫苗可以增强免疫反应及诱导HER2阳性DCIS病情缓解

HER-2抗原冲击DC1制备的疫苗可以刺激HER-2特异性T细胞反应。CLIN CANCER RES近期发表了一篇文章，评估该疫苗的安全性以及通过不同途径给药的免疫反应及临床效果

JAMA Oncology：新检测或能准确预测超低风险乳腺癌患者预后

乳腺癌死亡率趋势在过去十年中大幅下降，主要是由于关注早期发现和预防的公共宣传活动。然而，早期筛查也可能导致一些患者过度治疗。一项新的检测可能有助于确定死亡风险最低的乳腺癌患者，从而帮助她们避免不必要的侵袭性治疗。该研究的主要作者是UCHealth的乳腺癌专家和外科医生Laura J. Esserman博士。研究结果发表在《JAMA Oncology》杂志上。

重复：基因组“暗物质”帮助科学家找到治疗乳腺癌新方法！

虽然蛋白质编码的基因突变在癌症基因组中占据了首要位置，但事实上，非编码基因在推动肿瘤生长的过程中也起着不容忽视的作用。近期，一项新的研究揭示了乳腺癌复发性突变等九个非编码元素。

正在招募患者：晚期癌症、乳腺癌、强直性脊柱炎、顽固性高血压大汇集

分享一次意味着让这些痛苦的患者有一次新药治疗的机会！临床试验是推动人类健康事业向前发展的重要手段，参加新药研究，可以使患者最早受益于这些新药的治疗，可能获得好的治疗，尤其对于复发难治的患者，目前已经上市的药物没有好的治疗效果时，临床试验新药是首选治疗。【梅斯医学-患者招募】已建立临床试验推荐中心，目前已有多种相关药物临床试验，覆盖心血管、肿瘤、内分泌、骨科等领域。愿意与广大临床医生、以及药企和CR

Nat Genet：研究发现浸润性小叶癌新型驱动基因

浸润性小叶癌 (Invasive lobular carcinoma, ILC)是乳腺癌中常见的第二大亚型，占乳腺癌总体病例的8-14%。尽管在人体中，大多数浸润性小叶癌以上皮细胞钙黏蛋白（CDH1）的功能缺失为特征，小鼠模型中Cdh1的失活并不会使其更容易患乳腺肿瘤，这就说明在小鼠中，浸润性小叶癌的形成还需要积累其他基因上的突变。